---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-003381"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2026-05-13T21:15:17+00:00"
generated_at: "2026-05-13T21:17:24.000686+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aptose Q1 net loss $7.6M, cash $4.1M; Hanmi acquisition delayed, TUS data at EHA

## Summary
- Net loss of $7.6M ($2.99/share) for Q1 2026 vs $5.5M ($2.61/share) in Q1 2025.
- Cash and restricted cash $4.1M; working capital deficit $5.1M; relies on Hanmi advances to fund operations.
- Hanmi acquisition delayed due to pending Korean regulatory approvals; target close May 2026 at C$2.41/share (28% premium).
- TUS+VEN+AZA triplet data from TUSCANY trial selected for oral presentation at EHA2026 Congress in June.
- Luxeptinib license rights returned to CGI; program winding down.

## SEC filing metadata
- accession: 0001171843-26-003381
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2026-05-13T21:15:17+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184326003381/0001171843-26-003381-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184326003381/f8k_051326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-003381
- JSON: https://secwatch.observer/filing/0001171843-26-003381.json
- Plain text: https://secwatch.observer/filing/0001171843-26-003381.txt

## Key facts
- Earnings Releases
  Aptose Biosciences Inc. reported the first quarter ended March 31, 2026 results: net income $7.6 million, EPS $(2.99) per common share, basic and diluted.
  - Period: the first quarter ended March 31, 2026
  - Net income: $7.6 million
  - EPS: $(2.99) per common share, basic and diluted
  - Result: reported results
  source text: Net loss per common share, basic and diluted $ (2.99 )
  evidence_url: https://www.sec.gov/Archives/edgar/data/882361/000117184326003381/0001171843-26-003381-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.